⌕ Поиск по атласу

NIST · ИТ · 9935317403c14aa31a81

9935317403c14aa31a81 · Data Sets for the Qualification of Volumetric CT as a Quantitative Imaging Biomarker in Lung Cancer

Data Sets for the Qualification of Volumetric CT as a Quantitative Imaging Biomarker in Lung Cancer

The drug development industry is faced with increasing costs and decreasing success rates. New ways to understand biology as well as the increasing interest in personalized treatments for smaller patient segments requires new capabilities for the rapid

Официальный источник · 2010-10-20

Полные импортированные сведения карточки
{
  "title_en": "Data Sets for the Qualification of Volumetric CT as a Quantitative Imaging Biomarker in Lung Cancer",
  "designation": "",
  "series": "",
  "status": "",
  "date": "2010-10-20",
  "date_original": "October 20, 2010",
  "url": "https://www.nist.gov/publications/data-sets-qualification-volumetric-ct-quantitative-imaging-biomarker-lung-cancer",
  "source": "NIST Publications",
  "display_en": "",
  "authors_en": "Charles D. Fenimore , Andrew Buckler, Lawrence H. Schwartz, Nicholas Petrick, Michael McNitt-Gray, Binsheng Zhao, Anthony P. Reeves, P. David Mozeley, Ricardo S. Avila",
  "abstract_excerpt_en": "The drug development industry is faced with increasing costs and decreasing success rates. New ways to understand biology as well as the increasing interest in personalized treatments for smaller patient segments requires new capabilities for the rapid",
  "id": "9935317403c14aa31a81",
  "sources": [
    "NIST Publications"
  ],
  "source_records": [
    {
      "title_en": "Data Sets for the Qualification of Volumetric CT as a Quantitative Imaging Biomarker in Lung Cancer",
      "designation": "",
      "series": "",
      "status": "",
      "date": "2010-10-20",
      "date_original": "October 20, 2010",
      "url": "https://www.nist.gov/publications/data-sets-qualification-volumetric-ct-quantitative-imaging-biomarker-lung-cancer",
      "source": "NIST Publications",
      "display_en": "",
      "authors_en": "Charles D. Fenimore , Andrew Buckler, Lawrence H. Schwartz, Nicholas Petrick, Michael McNitt-Gray, Binsheng Zhao, Anthony P. Reeves, P. David Mozeley, Ricardo S. Avila",
      "abstract_excerpt_en": "The drug development industry is faced with increasing costs and decreasing success rates. New ways to understand biology as well as the increasing interest in personalized treatments for smaller patient segments requires new capabilities for the rapid"
    }
  ],
  "translation_state": "none"
}